How we treat higher-risk myelodysplastic syndromes

Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS)

(2013) W. Saber et al.   BLOOD

Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet

(2013) L. Malcovati et al.   BLOOD

Who is the better donor for older hematopoietic transplant recipients: an older-aged sibling or a young, matched unrelated volunteer?

(2013) A. M. Alousi et al.   BLOOD

How we treat lower-risk myelodysplastic syndromes

(2013) P. Fenaux et al.   BLOOD

Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes

(2013) Rami S. Komrokji et al.   BRITISH JOURNAL OF HAEMATOLOGY

Randomized Open-Label Phase II Study of Decitabine in Patients With Low- or Intermediate-Risk Myelodysplastic Syndromes

(2013) Guillermo Garcia-Manero et al.   JOURNAL OF CLINICAL ONCOLOGY

Role of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem-Cell Transplantation in Older Patients With De Novo Myelodysplastic Syndromes: An International Collaborative Decision Analysis

(2013) John Koreth et al.   JOURNAL OF CLINICAL ONCOLOGY

Clonal diversity of recurrently mutated genes in myelodysplastic syndromes

(2013) M J Walter et al.   LEUKEMIA

Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia

(2013) E H Estey   LEUKEMIA

Allogeneic Hematopoietic Cell Transplantation in Patients Age 60-70 Years with De Novo High-Risk Myelodysplastic Syndrome or Secondary Acute Myelogenous Leukemia: Comparison with Patients Lacking Donors Who Received Azacitidine

(2012) Uwe Platzbecker et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Pretransplantation Therapy with Azacitidine vs Induction Chemotherapy and Posttransplantation Outcome in Patients with MDS

(2012) Aaron T. Gerds et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes

(2012) V. Visconte et al.   BLOOD

Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes

(2012) M. A. Sekeres et al.   BLOOD

Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis

(2012) H. Makishima et al.   BLOOD

Revised International Prognostic Scoring System for Myelodysplastic Syndromes

(2012) P. L. Greenberg et al.   BLOOD

Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS

(2012) H. J. Deeg et al.   BLOOD

Detection of copy number alterations in acute myeloid leukemia and myelodysplastic syndromes

(2012) Meagan A Jacoby et al.   EXPERT REVIEW OF MOLECULAR DIAGNOSTICS

Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia and del(5q): results of the LENAMAINT trial

(2012) K. Sockel et al.   HAEMATOLOGICA

Impact of Azacitidine Before Allogeneic Stem-Cell Transplantation for Myelodysplastic Syndromes: A Study by the Société Française de Greffe de Moelle et de Thérapie-Cellulaire and the Groupe-Francophone des Myélodysplasies

(2012) Gandhi Damaj et al.   JOURNAL OF CLINICAL ONCOLOGY

Validation of a Prognostic Model and the Impact of Mutations in Patients With Lower-Risk Myelodysplastic Syndromes

(2012) Rafael Bejar et al.   JOURNAL OF CLINICAL ONCOLOGY

New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge

(2012) Julie Schanz et al.   JOURNAL OF CLINICAL ONCOLOGY

Emerging roles of the spliceosomal machinery in myelodysplastic syndromes and other hematological disorders

(2012) V Visconte et al.   LEUKEMIA

Allogeneic stem cell transplantation for older advanced MDS patients: improved survival with young unrelated donor in comparison with HLA-identical siblings

(2012) N Kröger et al.   LEUKEMIA

Clonal Architecture of Secondary Acute Myeloid Leukemia

(2012) Matthew J. Walter et al.   NEW ENGLAND JOURNAL OF MEDICINE

p53-Independent, Normal Stem Cell Sparing Epigenetic Differentiation Therapy for Myeloid and Other Malignancies

(2012) Yogen Saunthararajah et al.   SEMINARS IN ONCOLOGY

Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies

(2011) R. V. Tiu et al.   BLOOD

Rare occurrence of DNMT3A mutations in myelodysplastic syndromes

(2011) F. Thol et al.   HAEMATOLOGICA

Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities

(2011) L. Mollgard et al.   HAEMATOLOGICA

Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure

(2011) Thomas Prébet et al.   JOURNAL OF CLINICAL ONCOLOGY

Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group

(2011) Michael Lübbert et al.   JOURNAL OF CLINICAL ONCOLOGY

Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic Study of 277 patients

(2011) M M Patnaik et al.   LEUKEMIA

Recurrent DNMT3A mutations in patients with myelodysplastic syndromes

(2011) M J Walter et al.   LEUKEMIA

Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias

(2011) R Itzykson et al.   LEUKEMIA

Comprehensive array CGH of normal karyotype myelodysplastic syndromes reveals hidden recurrent and individual genomic copy number alterations with prognostic relevance

(2011) A Thiel et al.   LEUKEMIA

Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na

(2011) Mahesh Seetharam et al.   LEUKEMIA RESEARCH

Frequent pathway mutations of splicing machinery in myelodysplasia

(2011) Kenichi Yoshida et al.   NATURE

Cancer epigenetics reaches mainstream oncology

(2011) Manuel Rodríguez-Paredes et al.   NATURE MEDICINE

Clinical Effect of Point Mutations in Myelodysplastic Syndromes

(2011) Rafael Bejar et al.   NEW ENGLAND JOURNAL OF MEDICINE

Perceptions of Disease State, Treatment Outcomes, and Prognosis Among Patients with Myelodysplastic Syndromes: Results from an Internet-Based Survey

(2011) M. A. Sekeres et al.   ONCOLOGIST

Combining Clinical, Pathological, and Demographic Factors Refines Prognosis of Lung Cancer: A Population-Based Study

(2011) Joseph Putila et al.   PLoS One

Microarray-based comparative genomic hybridization of cancer targets reveals novel, recurrent genetic aberrations in the myelodysplastic syndromes

(2011) Kathryn A. Kolquist et al.   Cancer Genetics

Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromes

(2010) Mikkael A. Sekeres et al.   AMERICAN JOURNAL OF HEMATOLOGY

Overexpression of the EZH2, RING1 and BMI1 genes is common in myelodysplastic syndromes: relation to adverse epigenetic alteration and poor prognostic scoring

(2010) Feng Xu et al.   ANNALS OF HEMATOLOGY

Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias

(2010) Julien Rocquain et al.   BMC CANCER

Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome

(2010) Celeste Bello et al.   CANCER

Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome

(2010) Marcos de Lima et al.   CANCER

Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy

(2010) Elias Jabbour et al.   CANCER

Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial

(2010) T. de Witte et al.   HAEMATOLOGICA

Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome

(2010) M. G. Della Porta et al.   HAEMATOLOGICA

Molecular mechanisms that produce secondary MDS/AML byRUNX1/AML1point mutations

(2010) Yuka Harada et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Phase I Combination Trial of Lenalidomide and Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes

(2010) Mikkael A. Sekeres et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of Age on Outcome of Reduced-Intensity Hematopoietic Cell Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission or With Myelodysplastic Syndrome

(2010) Brian L. McClune et al.   JOURNAL OF CLINICAL ONCOLOGY

Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia

(2010) J Boultwood et al.   LEUKEMIA

Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies

(2010) H Makishima et al.   LEUKEMIA

Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms

(2010) O Kosmider et al.   LEUKEMIA

Decitabine Maintains Hematopoietic Precursor Self-Renewal by Preventing Repression of Stem Cell Genes by a Differentiation-Inducing Stimulus

(2010) Z. Hu et al.   MOLECULAR CANCER THERAPEUTICS

TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs)

(2009) O. Kosmider et al.   BLOOD

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

(2009) J. W. Vardiman et al.   BLOOD

Non-intensive treatment with low-dose 5-aza-2′-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients

(2009) M Lübbert et al.   BONE MARROW TRANSPLANTATION

5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation

(2009) T Field et al.   BONE MARROW TRANSPLANTATION

Application of array-based whole genome scanning technologies as a cytogenetic tool in haematological malignancies

(2009) Jaroslaw P. Maciejewski et al.   BRITISH JOURNAL OF HAEMATOLOGY

Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations

(2009) Yuka Harada et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Multicenter Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Myelodysplastic Syndromes: The Alternative Dosing for Outpatient Treatment (ADOPT) Trial

(2009) David P. Steensma et al.   JOURNAL OF CLINICAL ONCOLOGY

Mutations of E3 Ubiquitin Ligase Cbl Family Members Constitute a Novel Common Pathogenic Lesion in Myeloid Malignancies

(2009) Hideki Makishima et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Clinical and Pharmacokinetic Study of Oral Sapacitabine in Patients With Acute Leukemia and Myelodysplastic Syndrome

(2009) Hagop Kantarjian et al.   JOURNAL OF CLINICAL ONCOLOGY

DNA Methylation Predicts Survival and Response to Therapy in Patients With Myelodysplastic Syndromes

(2009) Lanlan Shen et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

(2009) Pierre Fenaux et al.   LANCET ONCOLOGY

Acquired mutations in TET2 are common in myelodysplastic syndromes

(2009) Saskia M C Langemeijer et al.   NATURE GENETICS

Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs

(2008) D. E. Rollison et al.   BLOOD

Aberrant DNA methylation is a dominant mechanism in MDS progression to AML

(2008) Y. Jiang et al.   BLOOD

Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System

(2008) Hagop Kantarjian et al.   CANCER

Common troublesome symptoms and their impact on quality of life in patients with myelodysplastic syndromes (MDS): Results of a large internet-based survey

(2007) David P. Steensma et al.   LEUKEMIA RESEARCH